42 results on '"Tagarro, I"'
Search Results
2. P611 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN’S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
- Author
-
Muñoz Nuñez, J F, primary, Rodríguez, C, additional, Gisbert, J P, additional, Bernardo, S, additional, Aparicio, J, additional, Tagarro, I, additional, and Casellas, F, additional
- Published
- 2023
- Full Text
- View/download PDF
3. P779 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
- Author
-
Casellas Jorda, F, primary, Rodríguez, C, additional, Gisbert, J P, additional, Bernardo, S, additional, Aparicio, J, additional, Tagarro, I, additional, and Muñoz, F, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNF alpha used for the treatment of IBD: Results from the VERNE study
- Author
-
Batista, G, Marin-Jimenez, I, Fores, A, Garcia-Planella, E, Arguelles-Arias, F, Tagarro, I, Fernandez-Nistal, A, Montoto, C, Aparicio, J, Aguas, M, Santos-Fernandez, J, Bosca-Watts, MM, Ferreiro-Iglesias, R, Merino, O, Aldeguer, X, Corttes, X, Sicilia, B, Mesonero, F, and Barreiro-de Acosta, M
- Subjects
Anti-TNF alpha ,Treatment discontinuation ,Treatment intensification ,Inflammatory bowel disease - Abstract
Background: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the treatment patterns with the first anti-TNF alpha in IBD. Methods: Retrospective, observational study. Results: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. Conclusions: Around one-third of IBD biologic-naive patients treated with an anti-TNF alpha required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNF alpha due to inappropriate disease control. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
- Published
- 2022
5. Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis
- Author
-
Finn AL, Hill WDC, Tagarro I, and Gever LN
- Subjects
Medicine (General) ,R5-920 - Abstract
Andrew L Finn1, WD Charlie Hill2, Ignacio Tagarro3, Larry N Gever41Product Development, BioDelivery Sciences International, Inc, Raleigh, NC, USA; 2Co-founding partner, InVisions Consultants, LLC, San Antonio, TX, USA; 3Marketing Centre CIP CNS, Meda Pharma S.A.U., Madrid, Spain; 4Medical Affairs, Meda Pharmaceuticals, Inc, Somerset, NJ, USAPurpose: Fentanyl buccal soluble film (FBSF) consists of a small, bilayered, water-soluble polymer film that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. The purpose of this study was to evaluate the absorption of fentanyl from FBSF in patients with cancer, with and without grade 1 oral mucositis, and to assess the tolerability of FBSF in this patient population.Patients and methods: In an open-label, single-dose study, two groups of opioid-naive patients (ie, not receiving opioids on a regular basis) with cancer received a 200 µg dose of FBSF. Patients in cohort I (n = 7) had grade 1 mucositis, and patients in cohort II (n = 7) were age- and gender-matched controls without mucositis. The FBSF dose was placed on the area of mucositis in cohort I and on a matching location in cohort II. Blood samples were collected up to 4 hours after administration, and safety assessments were made throughout the study.Results: Peak plasma concentration and area under the concentration–time curve from time 0 to 4 hours post-dose values of patients in the grade 1 mucositis cohort were lower than those observed in patients without mucositis. There was no application site irritation reported in any patient, regardless of mucositis status. Mild somnolence was reported by two patients with mucositis. There were no deaths or serious adverse events reported in this study.Conclusion: The results of this study indicate that application of FBSF to an area of grade 1 mucositis does not result in increased fentanyl exposure or irritation of the mucosa. The 200 µg dose of FBSF was well tolerated.Keywords: breakthrough cancer pain, clinical study, application site pain
- Published
- 2011
6. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study
- Author
-
Rauck, R., North, J., Gever, L.N., Tagarro, I., and Finn, A.L.
- Published
- 2010
- Full Text
- View/download PDF
7. Impact of comorbidities on anti-TNF alpha response and relapse in patients with inflammatory bowel disease: the VERNE study
- Author
-
Marin-Jimenez, I, Bastida, G, Fores, A, Garcia-Planella, E, Arguelles-Arias, F, Sarasa, P, Tagarro, I, Fernandez-Nistal, A, Montoto, C, Aguas, M, Santos-Fernandez, J, Bosca-Watts, MM, Ferreiro, R, Merino, O, Aldeguer, X, Cortes, X, Sicilia, B, Mesonero, F, and Barreiro-de Acosta, M
- Subjects
Crohn's disease, TNF-alpha, immune response, ulcerative colitis ,digestive system diseases - Abstract
Objective To evaluate the impact of comorbidities and extraintestinal manifestations of inflammatory bowel disease on the response of patients with inflammatory bowel disease to antitumour necrosis factor alpha (anti-TNF alpha) therapy. Design Data from 310 patients (194 with Crohn's disease and 116 with ulcerative colitis) treated consecutively with the first anti-TNF alpha in 24 Spanish hospitals were retrospectively analysed. Univariate and multivariate logistic regression analyses were performed to assess the associations between inflammatory bowel disease comorbidities and extraintestinal manifestations with anti-TNF alpha treatment outcomes. Key clinical features, such as type of inflammatory bowel disease and concomitant treatments, were included as fixed factors in the model. Results Multivariate logistic regression analyses (OR, 95% CI) showed that chronic obstructive pulmonary disease (2.67, 1.33 to 5.35) and hepato-pancreato-biliary diseases (1.87, 1.48 to 2.36) were significantly associated with primary non-response to anti-TNF alpha, as was the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn's disease). It was also found that myocardial infarction (3.30, 1.48 to 7.35) and skin disease (2.73, 1.42 to 5.25) were significantly associated with loss of response, along with the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn's disease). Conclusions Our results suggest that the presence of some comorbidities in patients with inflammatory bowel disease, such as chronic obstructive pulmonary disease and myocardial infarction, and of certain extraintestinal manifestations of inflammatory bowel disease, such as hepato-pancreato-biliary conditions and skin diseases, appear to be related to failure to anti-TNF alpha treatment. Therefore, their presence should be considered when choosing a treatment.
- Published
- 2020
8. Effect of a Simple Dose-Escalation Schedule on Tramadol Tolerability: Assessment in the Clinical Setting
- Author
-
Tagarro, I., Herrera, J., Barutell, C., Díez, M. C., Marín, M., Samper, D., Busquet, C., and Rodríguez, M. J.
- Published
- 2005
- Full Text
- View/download PDF
9. Digestion of centromeric DNA from each human metaphase chromosome by the 6 bp-restriction enzyme StuI
- Author
-
Tagarro, I., Fernández-Peralta, A. M., and González-Aguilera, J. J.
- Published
- 1993
- Full Text
- View/download PDF
10. Time-dependent AluI action on human chromosomes
- Author
-
Fernández-Peralta, A. Ma., Tagarro, I., Ludeña Reyes, P., Sentís Castaño, C., Fernández Piqueras, J., and González-Aguilera, J. J.
- Published
- 1991
- Full Text
- View/download PDF
11. P309 Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study
- Author
-
Marín-Jiménez, I, primary, Bastida, G, additional, Forés, A, additional, García-Planella, E, additional, Argüelles-Arias, F, additional, Sarasa, P, additional, Tagarro, I, additional, Fernández-Nistal, A, additional, Montoto, C, additional, Aguas, M, additional, Santos-Fernández, J, additional, Boscá, M, additional, Ferreiro-Iglesias, R, additional, Merino, O, additional, Aldeguer, X, additional, Cortés, X, additional, Sicilia, B, additional, Mesonero, F, additional, and Barreiro-de Acosta, M, additional
- Published
- 2019
- Full Text
- View/download PDF
12. P127 Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study)
- Author
-
Bastida, G, primary, Marín-Jiménez, I, additional, Forés, A, additional, García-Planella, E, additional, Argüelles-Arias, F, additional, Sarasa, P, additional, Tagarro, I, additional, Fernández-Nistal, A, additional, Montoto, C, additional, Aguas, M, additional, Santos-Fernández, J, additional, Boscá, M, additional, Ferreiro-Iglesias, R, additional, Merino, O, additional, Aldeguer, X, additional, Cortés, X, additional, Sicilia, B, additional, Mesonero, F, additional, and Barreiro-de Acosta, M, additional
- Published
- 2019
- Full Text
- View/download PDF
13. BEMA Fentanyl produziert eine schnellere und höhere Absorption als ACTIQ®, sowie eine hohe pharmakokinetische Reproduzierbarkeit
- Author
-
Tagarro, I, primary, Zandt, D, additional, Vasisht, N, additional, Finn, A, additional, and Stark, J, additional
- Published
- 2008
- Full Text
- View/download PDF
14. Azelastine Tablets in the Treatment of Chronic Idiopathic Urticaria
- Author
-
Camarasa, J.M.G., primary, Aliaga, A., additional, Fernández-Vozmediano, J.M., additional, Fonseca, E., additional, Iglesias, L., additional, and Tagarro, I., additional
- Published
- 2001
- Full Text
- View/download PDF
15. Digestion of human chromosomes by means of the isoschizomers MspI and HpaII
- Author
-
Fernandez-Peralta, A. M., primary, Navarro, P., additional, Tagarro, I., additional, and Gonzalez-Aguilera, J. J., additional
- Published
- 1994
- Full Text
- View/download PDF
16. Distribution of TaqI sites along human chromosomes revealed by in situ enzyme-nick translation
- Author
-
Tagarro, I., primary, Gonzalez-Aguilera, J. J., additional, Fernandez-Peralta, A. M., additional, Stefano, G. F. de, additional, and Ferrucci, L., additional
- Published
- 1993
- Full Text
- View/download PDF
17. Distribution of satellite DNA fractions within major heterochromatic regions of human chromosomes as revealed by PleI and TfiI digestion
- Author
-
Tagarro, I., primary, Fernández-Peralta, A.M., additional, and González-Aguilera, J.J., additional
- Published
- 1992
- Full Text
- View/download PDF
18. Induction of R-bands on human chromosomes by TfiI as the consequence of local differences in target richness
- Author
-
Tagarro, I., primary, González-Aguilera, J.J., additional, and Fernández-Peralta, A.M., additional
- Published
- 1992
- Full Text
- View/download PDF
19. TaqI digestion reveals fractions of satellite DNAs on human chromosomes
- Author
-
Tagarro, I., primary, González-Aguilera, J. J., additional, and Fernández-Peralta, A. Ma, additional
- Published
- 1991
- Full Text
- View/download PDF
20. Time-dependent AluI action on human chromosomes
- Author
-
Fern�ndez-Peralta, A. Ma., primary, Tagarro, I., additional, Lude�a Reyes, P., additional, Sent�s Casta�o, C., additional, Fern�ndez Piqueras, J., additional, and Gonz�lez-Aguilera, J. J., additional
- Published
- 1991
- Full Text
- View/download PDF
21. Azelastine Tablets in the Treatment of Chronic Idiopathic Urticaria.
- Author
-
Camarasa, J.M.G., Aliaga, A., Fernández-Vozmediano, J.M., Fonseca, E., Iglesias, L., and Tagarro, I.
- Published
- 2001
- Full Text
- View/download PDF
22. Distribution of satellite DNA fractions within major heterochromatic regions of human chromosomes as revealed by PleI and TfiI digestion.
- Author
-
Tagarro, I., Fernández-Peralta, A.M., and González-Aguilera, J.J.
- Published
- 1992
- Full Text
- View/download PDF
23. Induction of R-bands on human chromosomes by TfiI as the consequence of local differences in target richness.
- Author
-
Tagarro, I., González-Aguilera, J.J., and Fernández-Peralta, A.M.
- Published
- 1992
- Full Text
- View/download PDF
24. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease
- Author
-
Julián Panés, Damián García-Olmo, Gert Van Assche, Jean Frederic Colombel, Walter Reinisch, Daniel C. Baumgart, Axel Dignass, Maria Nachury, Marc Ferrante, Lili Kazemi-Shirazi, Jean C. Grimaud, Fernando de la Portilla, Eran Goldin, Marie Paule Richard, Mary Carmen Diez, Ignacio Tagarro, Anne Leselbaum, Silvio Danese, Jean F. Colombel, Anton Stift, Jörg Tschmelitsch, Karl Mrak, Herbert Tilg, Irmgard Kroberger, André D’Hoore, Danny De Looze, Filip Baert, Paul Pattyn, Philippe Zerbib, Frank Zerbib, Stéphanie Viennot, Jean-Louis Dupas, Pierre-Charles Orsoni, Xavier Hebuterne, Amine Rahili, Matthieu Allez, Yves Panis, Max Reinshagen, Roland Scherer, Andreas Sturm, Wolfgang Kruis, Daniel-Simon Duek, Matti Waterman, Adi Lahat-Zok, Oded Zmora, Hagit Tulchinsky, Yair Edden, Antonino Spinelli, Vito Annese, Imerio Angriman, Gabriele Riegler, Francesco Selvaggi, Bas Oldenburg, Lennard Gilissen, Gust Van Montfort, Mark Lowenberg, Adrianus Willem Bemelman, Raúl Almenara, María Dolores Martín Arranz, Mariano García-Arranz, Javier Pérez Gisbert, Rosana Palasí, Carlos Taxonera Samsó, Jose Manuel Herrera Justiniano, Ricardo Rada, Mª Teresa Butrón, Daniel Carpio López, Antonio López-Sanromán, Joaquín Hinojosa de Val, Amparo Solana, F. Xavier González Argenté, Carlos Pastor, Hector Guadalajara, Panes, J, Garcia-Olmo, D, Van Assche, G, Colombel, Jf, Reinisch, W, Baumgart, Dc, Dignass, A, Nachury, M, Ferrante, M, Kazemi-Shirazi, L, Grimaud, Jc, de la Portilla, F, Goldin, E, Richard, Mp, Diez, Mc, Tagarro, I, Leselbaum, A, Danese, S, Panes, J., Garcia-Olmo, D., Van Assche, G., Colombel, J. F., Reinisch, W., Baumgart, D. C., Dignass, A., Nachury, M., Ferrante, M., Kazemi-Shirazi, L., Grimaud, J. C., de la Portilla, F., Goldin, E., Richard, M. P., Diez, M. C., Tagarro, I., Leselbaum, A., Danese, S., Stift, A., Tschmelitsch, J., Mrak, K., Tilg, H., Kroberger, I., D'Hoore, A., De Looze, D., Baert, F., Pattyn, P., Zerbib, P., Zerbib, F., Viennot, S., Dupas, J. -L., Orsoni, P. -C., Hebuterne, X., Rahili, A., Allez, M., Panis, Y., Reinshagen, M., Scherer, R., Sturm, A., Kruis, W., Duek, D. -S., Waterman, M., Lahat-Zok, A., Zmora, O., Tulchinsky, H., Edden, Y., Spinelli, A., Annese, V., Angriman, I., Riegler, G., Selvaggi, F., Oldenburg, B., Gilissen, L., Van Montfort, G., Lowenberg, M., Bemelman, A. W., Almenara, R., Martin Arranz, M. D., Garcia-Arranz, M., Perez Gisbert, J., Palasi, R., Samso, C. T., Herrera Justiniano, J. M., Rada, R., Butron, M. T., Lopez, D. C., Lopez-Sanroman, A., Hinojosa de Val, J., Solana, A., Gonzalez Argente, F. X., Pastore, Concetta, Guadalajara, H., Gastroenterology and Hepatology, and AGEM - Digestive immunity
- Subjects
Male ,Time Factors ,Intention to Treat Analysi ,medicine.medical_treatment ,Gastroenterology ,0302 clinical medicine ,Crohn Disease ,Risk Factors ,Clinical endpoint ,Israel ,Transplantation, Homologou ,Crohn's disease ,education.field_of_study ,medicine.diagnostic_test ,Remission Induction ,Stem-cell therapy ,Magnetic Resonance Imaging ,Intention to Treat Analysis ,Europe ,Treatment Outcome ,Adipose Tissue ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Clinical Remission ,Human ,Adult ,Homologous ,medicine.medical_specialty ,Time Factor ,Population ,Placebo ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,medicine ,Transplantation, Homologous ,Humans ,Rectal Fistula ,education ,Adverse effect ,Transplantation ,Intention-to-treat analysis ,Hepatology ,business.industry ,Risk Factor ,Cell Therapy ,Magnetic resonance imaging ,Anal Fistula ,Combined Remission ,Stem Cell Transplantation ,medicine.disease ,business - Abstract
Background & Aims: Therapies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-term healing. We performed a randomized placebo-controlled trial to determine the long-term efficacy and safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) in patients with Crohn's disease and perianal fistulas. Methods: We performed a double-blind study at 49 hospitals in Europe and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, complex perianal fistulas. Patients were randomly assigned (1:1) to groups given a single local injection of 120 million Cx601 cells or placebo (control), in addition to the standard of care. Efficacy endpoints evaluated in the modified intention-to-treat population (randomly assigned, treated, and with 1 or more post-baseline efficacy assessment) at week 52 included combined remission (closure of all treated external openings draining at baseline with absence of collections >2 cm, confirmed by magnetic resonance imaging) and clinical remission (absence of draining fistulas). Results: The study's primary endpoint, at week 24, was previously reported (combined remission in 51.5% of patients given Cx601 vs 35.6% of controls, for a difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5–31.2; P =.021). At week 52, a significantly greater proportion of patients given Cx601 achieved combined remission (56.3%) vs controls (38.6%) (a difference of 17.7 percentage points; 95% CI 4.2–31.2; P =.010), and clinical remission (59.2% vs 41.6% of controls, for a difference of 17.6 percentage points; 95% CI 4.1–31.1; P =.013). Safety was maintained throughout week 52; adverse events occurred in 76.7% of patients in the Cx601 group and 72.5% of patients in the control group. Conclusion: In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex perianal fistulas, we found Cx601 to be safe and effective in closing external openings, compared with placebo, after 1 year. ClinicalTrials.gov no: NCT01541579.
- Published
- 2018
25. Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study.
- Author
-
Gomollón F, Gisbert JP, Guerra I, Plaza R, Pajares Villarroya R, Moreno Almazán L, López Martín MC, Domínguez Antonaya M, Vera Mendoza MI, Aparicio J, Martínez V, Tagarro I, Fernández-Nistal A, Lumbreras S, Maté C, and Montoto C
- Subjects
- Humans, Machine Learning, Natural Language Processing, Pilot Projects, Prognosis, Recurrence, Retrospective Studies, Biological Products therapeutic use, Crohn Disease diagnosis, Crohn Disease drug therapy
- Abstract
Background: The impact of relapses on disease burden in Crohn's disease (CD) warrants searching for predictive factors to anticipate relapses. This requires analysis of large datasets, including elusive free-text annotations from electronic health records. This study aims to describe clinical characteristics and treatment with biologics of CD patients and generate a data-driven predictive model for relapse using natural language processing (NLP) and machine learning (ML)., Methods: We performed a multicenter, retrospective study using a previously validated corpus of CD patient data from eight hospitals of the Spanish National Healthcare Network from 1 January 2014 to 31 December 2018 using NLP. Predictive models were created with ML algorithms, namely, logistic regression, decision trees, and random forests., Results: CD phenotype, analyzed in 5938 CD patients, was predominantly inflammatory, and tobacco smoking appeared as a risk factor, confirming previous clinical studies. We also documented treatments, treatment switches, and time to discontinuation in biologics-treated CD patients. We found correlations between CD and patient family history of gastrointestinal neoplasms. Our predictive model ranked 25 000 variables for their potential as risk factors for CD relapse. Of highest relative importance were past relapses and patients' age, as well as leukocyte, hemoglobin, and fibrinogen levels., Conclusion: Through NLP, we identified variables such as smoking as a risk factor and described treatment patterns with biologics in CD patients. CD relapse prediction highlighted the importance of patients' age and some biochemistry values, though it proved highly challenging and merits the assessment of risk factors for relapse in a clinical setting., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
26. Evaluation of Natural Language Processing for the Identification of Crohn Disease-Related Variables in Spanish Electronic Health Records: A Validation Study for the PREMONITION-CD Project.
- Author
-
Montoto C, Gisbert JP, Guerra I, Plaza R, Pajares Villarroya R, Moreno Almazán L, López Martín MDC, Domínguez Antonaya M, Vera Mendoza I, Aparicio J, Martínez V, Tagarro I, Fernandez-Nistal A, Canales L, Menke S, and Gomollón F
- Abstract
Background: The exploration of clinically relevant information in the free text of electronic health records (EHRs) holds the potential to positively impact clinical practice as well as knowledge regarding Crohn disease (CD), an inflammatory bowel disease that may affect any segment of the gastrointestinal tract. The EHRead technology, a clinical natural language processing (cNLP) system, was designed to detect and extract clinical information from narratives in the clinical notes contained in EHRs., Objective: The aim of this study is to validate the performance of the EHRead technology in identifying information of patients with CD., Methods: We used the EHRead technology to explore and extract CD-related clinical information from EHRs. To validate this tool, we compared the output of the EHRead technology with a manually curated gold standard to assess the quality of our cNLP system in detecting records containing any reference to CD and its related variables., Results: The validation metrics for the main variable (CD) were a precision of 0.88, a recall of 0.98, and an F1 score of 0.93. Regarding the secondary variables, we obtained a precision of 0.91, a recall of 0.71, and an F1 score of 0.80 for CD flare, while for the variable vedolizumab (treatment), a precision, recall, and F1 score of 0.86, 0.94, and 0.90 were obtained, respectively., Conclusions: This evaluation demonstrates the ability of the EHRead technology to identify patients with CD and their related variables from the free text of EHRs. To the best of our knowledge, this study is the first to use a cNLP system for the identification of CD in EHRs written in Spanish., (©Carmen Montoto, Javier P Gisbert, Iván Guerra, Rocío Plaza, Ramón Pajares Villarroya, Luis Moreno Almazán, María Del Carmen López Martín, Mercedes Domínguez Antonaya, Isabel Vera Mendoza, Jesús Aparicio, Vicente Martínez, Ignacio Tagarro, Alonso Fernandez-Nistal, Lea Canales, Sebastian Menke, Fernando Gomollón, PREMONITION-CD Study Group. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 18.02.2022.)
- Published
- 2022
- Full Text
- View/download PDF
27. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study.
- Author
-
Marin-Jimenez I, Bastida G, Forés A, Garcia-Planella E, Argüelles-Arias F, Sarasa P, Tagarro I, Fernández-Nistal A, Montoto C, Aguas M, Santos-Fernández J, Bosca-Watts MM, Ferreiro R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, and Barreiro-de Acosta M
- Subjects
- Comorbidity, Humans, Recurrence, Retrospective Studies, Colitis, Ulcerative complications, Colitis, Ulcerative drug therapy, Crohn Disease complications, Crohn Disease drug therapy, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
Objective: To evaluate the impact of comorbidities and extraintestinal manifestations of inflammatory bowel disease on the response of patients with inflammatory bowel disease to antitumour necrosis factor alpha (anti-TNFα) therapy., Design: Data from 310 patients (194 with Crohn's disease and 116 with ulcerative colitis) treated consecutively with the first anti-TNFα in 24 Spanish hospitals were retrospectively analysed. Univariate and multivariate logistic regression analyses were performed to assess the associations between inflammatory bowel disease comorbidities and extraintestinal manifestations with anti-TNFα treatment outcomes. Key clinical features, such as type of inflammatory bowel disease and concomitant treatments, were included as fixed factors in the model., Results: Multivariate logistic regression analyses (OR, 95% CI) showed that chronic obstructive pulmonary disease (2.67, 1.33 to 5.35) and hepato-pancreato-biliary diseases (1.87, 1.48 to 2.36) were significantly associated with primary non-response to anti-TNFα, as was the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn's disease). It was also found that myocardial infarction (3.30, 1.48 to 7.35) and skin disease (2.73, 1.42 to 5.25) were significantly associated with loss of response, along with the use of corticosteroids and the type of inflammatory bowel disease (ulcerative colitis vs Crohn's disease)., Conclusions: Our results suggest that the presence of some comorbidities in patients with inflammatory bowel disease, such as chronic obstructive pulmonary disease and myocardial infarction, and of certain extraintestinal manifestations of inflammatory bowel disease, such as hepato-pancreato-biliary conditions and skin diseases, appear to be related to failure to anti-TNFα treatment. Therefore, their presence should be considered when choosing a treatment., Trial Registration Number: NCT02861118., Competing Interests: Competing interests: IM-J has served as a consultant, advisory member, speaker, or has received research funding from MSD, AbbVie, Takeda, Tillotts, Ferring, Falk Pharma, Faes Farma, UCB Pharma, Otsuka Pharmaceutical, Shire, Gebro Pharma, and Chiesi. GB has received a speaker honorarium from AbbVie, Pfizer, Janssen, FAES, Takeda, Tillotts and Abbott. Also, GB has participated in the scientific advisory committees of Takeda, Janssen and AbbVie. EG-P has served as a speaker or received research or educational funding or advisory fees from MSD, AbbVie, Janssen, Ferring, Shire, Tillotts, and FAES. FA-A has served as a speaker, a consultant and as an advisory member for or have received research funding from Janssen, MSD, AbbVie, Pfizer, Kern Pharma, Biogen, Sandoz, Takeda, Ferring, Faes Farma, Shire Pharmaceuticals, Dr Falk Pharma, Tillotts Pharma, Gebro Pharma, Amgen and Vifor Pharma. IT, AF-N, and CM are full employees of Takeda Farmacéutica España. PS was a Takeda Farmacéutica España employee at the moment this work was conducted. MA has served as a speaker for MSD, AbbVie, Janssen, Takeda and Tillotts, and received educational grants from Janssen, MSD and AbbVie. JS-F has nothing to declare. MMB-W declares educational activities, research projects, scientific meetings and advisory boards sponsored by MSD, Ferring, AbbVie, Janssen and Takeda. RF has served as a speaker for or has received research funding from Takeda, MSD, AbbVie, Janssen, Palex, Shire Pharmaceuticals, Tillotts Pharma and Casen Recordati. OM has nothing to declare. MB-A has served as a speaker, a consultant and advisory board member for, or has received research funding from, MSD, AbbVie, Janssen, Pfizer, Kern Pharma, Biogen, Takeda, Ferring, Faes Farma, Shire Pharmaceuticals, Dr Falk Pharma, Tillotts Pharma, Chiesi, Gebro Pharma, Otsuka Pharmaceutical and Vifor Pharma., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
28. Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis.
- Author
-
García-Olmo D, Van Assche G, Tagarro I, Diez MC, Richard MP, Khalid JM, van Dijk M, Bennett D, Hokkanen SRK, and Panés J
- Subjects
- Adult, Europe epidemiology, Female, Humans, Incidence, Male, Middle Aged, Prevalence, Quality of Life, Recurrence, Time Factors, Treatment Outcome, Young Adult, Rectal Fistula epidemiology
- Abstract
Introduction: Despite the fact that perianal fistulas are associated with significant morbidity and impaired quality of life, their prevalence in Europe is unknown. The aim of this study was to estimate the prevalence of perianal fistulas in Europe, overall and according to etiology., Methods: Two independent literature reviews were performed using different search strategies to maximize the identification of potentially relevant studies. Data from relevant articles were used to estimate the prevalence of perianal fistulas in Europe. The robustness of the estimate was evaluated using data from a large population-based database from the UK., Results: A total of 26 studies provided epidemiological data on perianal fistulas, of which 16 provided suitable data to estimate the prevalence. Estimations using these data yielded a total prevalence of 1.69 per 10,000 population. Cryptoglandular infection and Crohn's disease (CD) were the predominant etiologies, with prevalence rates at 0.86 and 0.76 per 10,000 population, respectively. Comparison of prevalence data from the UK population-based database with the European population resulted in a standardized prevalence estimate of all perianal fistulas of 1.83 per 10,000 population, confirming the robustness of the literature-based estimate., Conclusion: Although in terms of incidence cryptoglandular fistulas were clearly predominant, the prevalence of fistulas in CD and cryptoglandular infection appeared more balanced. This is due to the longer duration and higher frequency of relapses of fistulas in CD. The estimated prevalence implies that perianal fistulas meet the criteria to be considered as a rare condition in Europe (prevalence less than 5 per 10,000 population)., Funding: This study was funded by Takeda Pharmaceutical U.S.A., Inc. and TiGenix SAU.
- Published
- 2019
- Full Text
- View/download PDF
29. Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis.
- Author
-
Schwartz DA, Tagarro I, Carmen Díez M, and Sandborn WJ
- Subjects
- Crohn Disease complications, Databases, Factual statistics & numerical data, Humans, Incidence, Prevalence, United States epidemiology, Crohn Disease epidemiology, Intestinal Fistula etiology
- Abstract
Background: Fistulas may arise as a relevant complication of Crohn's disease (CD). Despite their clinical significance and the substantial burden imposed on patients, limited data are available on the epidemiology of fistulizing CD in the United States., Methods: A systematic literature review was conducted to identify data published between 1970 and 2017 on the epidemiology of fistulas in patients with CD, with the aim to estimate the number of prevalent cases in the United States. Retrieved titles and abstracts were screened by 2 independent researchers for inclusion criteria (US population-based studies reporting data on the epidemiology of fistulizing CD). To validate the literature-based estimate, data from a US claims database (Truven Health MarketScan database) were analyzed. This database has broad geographic coverage, with health care data for >60 million patients during the period of the analysis., Results: The literature search retrieved 7 articles for full-text review, and only 1 met the criteria for inclusion. This study described the cumulative incidence of fistulas in a CD population from Minnesota over 20 years. From the reported data, the estimated number of prevalent cases with fistulizing CD in the United States was ~76,600 in 2017 (~52,900 anal, ~7400 rectovaginal, ~2300 enterocutaneous, and ~14,100 internal). Analysis from the US health care database resulted in an estimated number of ~75,700 patients, confirming the robustness of the original estimate from the literature., Conclusions: Based on 2 separate analyses, the estimated number of patients with fistulizing CD in the United States is ~77,000 patients., (© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2019
- Full Text
- View/download PDF
30. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.
- Author
-
Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, and Danese S
- Subjects
- Adult, Crohn Disease diagnosis, Double-Blind Method, Europe, Female, Humans, Intention to Treat Analysis, Israel, Magnetic Resonance Imaging, Male, Rectal Fistula diagnostic imaging, Rectal Fistula etiology, Remission Induction, Risk Factors, Time Factors, Transplantation, Homologous, Treatment Outcome, Adipose Tissue cytology, Crohn Disease complications, Rectal Fistula surgery, Stem Cell Transplantation adverse effects
- Abstract
Background & Aims: Therapies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-term healing. We performed a randomized placebo-controlled trial to determine the long-term efficacy and safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) in patients with Crohn's disease and perianal fistulas., Methods: We performed a double-blind study at 49 hospitals in Europe and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, complex perianal fistulas. Patients were randomly assigned (1:1) to groups given a single local injection of 120 million Cx601 cells or placebo (control), in addition to the standard of care. Efficacy endpoints evaluated in the modified intention-to-treat population (randomly assigned, treated, and with 1 or more post-baseline efficacy assessment) at week 52 included combined remission (closure of all treated external openings draining at baseline with absence of collections >2 cm, confirmed by magnetic resonance imaging) and clinical remission (absence of draining fistulas)., Results: The study's primary endpoint, at week 24, was previously reported (combined remission in 51.5% of patients given Cx601 vs 35.6% of controls, for a difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5-31.2; P = .021). At week 52, a significantly greater proportion of patients given Cx601 achieved combined remission (56.3%) vs controls (38.6%) (a difference of 17.7 percentage points; 95% CI 4.2-31.2; P = .010), and clinical remission (59.2% vs 41.6% of controls, for a difference of 17.6 percentage points; 95% CI 4.1-31.1; P = .013). Safety was maintained throughout week 52; adverse events occurred in 76.7% of patients in the Cx601 group and 72.5% of patients in the control group., Conclusion: In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex perianal fistulas, we found Cx601 to be safe and effective in closing external openings, compared with placebo, after 1 year. ClinicalTrials.gov no: NCT01541579., (Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
31. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.
- Author
-
Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, Blanco F, Martínez-Taboada VM, Taylor P, Martín-Martín C, DelaRosa O, Tagarro I, and Díaz-González F
- Subjects
- Adipose Tissue cytology, Adult, Aged, Arthritis, Rheumatoid immunology, Biomarkers blood, C-Reactive Protein metabolism, Female, Humans, Infusions, Intravenous, Male, Mesenchymal Stem Cell Transplantation adverse effects, Middle Aged, Severity of Illness Index, Single-Blind Method, Treatment Outcome, Arthritis, Rheumatoid therapy, Mesenchymal Stem Cell Transplantation methods
- Abstract
Objectives: To evaluate the safety and tolerability of the intravenous administration of Cx611, a preparation of allogeneic expanded adipose-derived stem cells (eASCs), in patients with refractory rheumatoid arthritis (RA), as well as to obtain preliminary clinical efficacy data in this population., Methods: It is a multicentre, dose escalation, randomised, single-blind (double-blind for efficacy), placebo-controlled, phase Ib/IIa clinical trial. Patients with active refractory RA (failure to at least two biologicals) were randomised to receive three intravenous infusions of Cx611: 1 million/kg (cohort A), 2 million/kg (cohort B), 4 million/kg (cohort C) or placebo, on days 1, 8 and 15, and they were followed for therapy assessment for 24 weeks., Results: Fifty-three patients were treated (20 in cohort A, 20 in cohort B, 6 in cohort C and 7 in placebo group). A total of 141 adverse events (AEs) were reported. Seventeen patients from the group A (85%), 15 from the group B (75%), 6 from the group C (100%) and 4 from the placebo group (57%) experienced at least one AE.Eight AEs from 6 patients were grade 3 in intensity (severe), 5 in cohort A (lacunar infarction, diarrhoea, tendon rupture, rheumatoid nodule and arthritis), 2 in cohort B (sciatica and RA) and 1 in the placebo group (asthenia). Only one of the grade 3 AEs was serious (the lacunar infarction). American College of Rheumatology 20 responses for cohorts A, B, C and placebo were 45%, 20%, 33% and 29%, respectively, at month 1, and 25%, 15%, 17% and 0%, respectively, at month 3., Conclusions: The intravenous infusion of Cx611 was in general well tolerated, without evidence of dose-related toxicity at the dose range and time period studied. In addition, a trend for clinical efficacy was observed. These data, in our opinion, justify further investigation of this innovative therapy in patients with RA., Trial Registration Numbers: EudraCT: 2010-021602-37; NCT01663116; Results., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
- Published
- 2017
- Full Text
- View/download PDF
32. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.
- Author
-
Gigante A and Tagarro I
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Drug Combinations, Gastrointestinal Diseases chemically induced, Gastrointestinal Diseases pathology, Humans, Ketoprofen administration & dosage, Ketoprofen adverse effects, Ketoprofen pharmacology, Medication Adherence, Omeprazole administration & dosage, Omeprazole adverse effects, Omeprazole pharmacology, Proton Pump Inhibitors adverse effects, Proton Pump Inhibitors pharmacology, Risk Factors, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Gastrointestinal Diseases prevention & control, Proton Pump Inhibitors administration & dosage
- Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed agents for rheumatic disorders such as osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Despite the known association between NSAID use and gastropathy, however, only around one-third of patients at risk of NSAID-induced gastrointestinal toxicity receive adequate gastroprotection, and as many as 44% of these patients are non-adherent. We review the co-prescription of proton pump inhibitors (PPIs) for the prevention of NSAID-induced gastropathy, with a particular focus on the first fixed-dose NSAID/PPI formulation: ketoprofen/omeprazole modified-release capsules. The ketoprofen/omeprazole fixed-dose combination is available in doses of 100 mg/20 mg, 150 mg/20 mg or 200 mg/20 mg as a single capsule for once-daily administration. Ketoprofen monotherapy has been shown to be generally equivalent to other NSAIDs when used in the treatment of OA. In RA, ketoprofen has demonstrated equivalent efficacy to diclofenac, indometacin, piroxicam, aceclofenac, phenylbutazone, naproxen and flurbiprofen. Studies comparing ketoprofen with ibuprofen and sulindac in patients with RA have, in general, favoured ketoprofen. Studies in AS have generally reported similar efficacy between ketoprofen and phenylbutazone and pirprofen. Prophylaxis with omeprazole is effective for the prevention of gastroduodenal ulcers, maintenance of remission and alleviation of dyspeptic symptoms in NSAID recipients. Omeprazole is well tolerated, and adverse events are generally gastrointestinal in nature. The fixed-dose combination of ketoprofen and omeprazole has demonstrated bioequivalence to the respective monotherapies. The incidence of digestive symptoms and the need for dose reduction was reported to be lower with the combination than with its components. Ketoprofen/omeprazole modified-release capsules are the first fixed-dose NSAID/PPI formulation to be approved. This formulation ensures compliance with the gastroprotective prophylaxis, as whenever the NSAID is taken, the PPI is co-administered. Additionally, the once-daily formulation has the potential to improve adherence to anti-inflammatory therapy., (© 2012 Adis Data Information BV. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
33. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study.
- Author
-
Finn AL, Vasisht N, Stark JG, Gever LN, and Tagarro I
- Subjects
- Adolescent, Adult, Area Under Curve, Cheek, Cross-Over Studies, Dose-Response Relationship, Drug, Female, Humans, Solubility, Analgesics, Opioid pharmacokinetics, Fentanyl pharmacokinetics
- Abstract
Background and Objectives: Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. It is approved for the treatment of cancer breakthrough pain in adult opioid-tolerant patients. The objective of this study was to evaluate the dose proportionality of the pharmacokinetics of FBSF in healthy subjects across a range of doses., Methods: This was a phase I, open-label, single-dose, three-period, Latin-square crossover study in which 12 healthy subjects received single FBSF doses of 200, 600 and 1200 μg with 72 hours between doses. Oral naltrexone was administered to each subject prior to and after each study dose. Serial venous blood samples were collected for 48 hours after study drug administration. Adverse events were recorded throughout the study. Dose linearity was examined using a power model (P = a × Doseb), where P represents the dependent variable (maximum plasma drug concentration [C(max)], area under the plasma concentration-time curve [AUC] from time zero to time of the last measurable concentration [AUC(last)], or AUC from time zero to infinity [AUC(∞)]), and a and b are constants. A value of b≈1 indicated linearity., Results: Following administration of FBSF doses of 200-1200 μg, mean C(max) values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19 ng/mL, respectively. Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL. All reported adverse events were considered to be mild to moderate in severity., Conclusions: This study demonstrates that peak fentanyl plasma concentrations and overall exposure increase in a dose-proportional manner following administration of FBSF.
- Published
- 2012
- Full Text
- View/download PDF
34. Intra- and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis.
- Author
-
Davies A, Finn A, and Tagarro I
- Subjects
- Administration, Buccal, Adult, Analgesics, Opioid administration & dosage, Area Under Curve, Fentanyl administration & dosage, Humans, Male, Solubility, Young Adult, Analgesics, Opioid pharmacokinetics, Fentanyl pharmacokinetics
- Abstract
Background and Objective: Breakthrough pain describes transient exacerbations of pain that occur in cancer patients with adequately controlled background pain. Transmucosal fentanyl administration produces rapid-onset and short-duration analgesia that is effective for treating patients with breakthrough pain. Although a significant amount of research has been devoted to the study of speed of analgesia onset of transmucosal fentanyl products, few data exist on their variability in absorption, particularly within the same individual, despite the importance of this characteristic to the dose-to-dose reliability of their analgesic effect. This cross-study analysis aimed to evaluate the intra- and interindividual pharmacokinetic differences of fentanyl administered via fentanyl buccal soluble film in healthy subjects., Methods: Data were evaluated from 24 subjects in two pharmacokinetic studies of fentanyl administered via fentanyl buccal soluble film (Breakyl®/Onsolis™; BEMA® [BioErodible MucoAdhesive] technology). In one study, 12 healthy subjects received 600 μg doses of fentanyl as single film on two separate occasions; in the second study, 12 different healthy subjects received 800 μg doses of fentanyl on two separate occasions, one as a single 800 μg film and the other as four 200 μg films., Results: The analysis showed a minimal intraindividual variability and a relatively higher interindividual variability in pharmacokinetic parameters (i.e. maximum plasma concentration, area under the plasma concentration-time curve from time zero to infinity). The coefficient of variation for intraindividual exposure to fentanyl variability was 7-10%, and for interindividual variability was 23-39%., Conclusion: The minimal intraindividual variability in fentanyl absorption from the buccal soluble film demonstrates a predictable dose-to-dose exposure, which is a very desirable attribute for a medicine that is intended to treat breakthrough cancer pain, suggesting that this product would be expected to produce consistent effects in clinical practice. The greater interindividual variability highlights the need for individual titration of this product (as occurs with similar transmucosal fentanyl products), and for the availability of an adequately wide dose range.
- Published
- 2011
- Full Text
- View/download PDF
35. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
- Author
-
Elsner F, Zeppetella G, Porta-Sales J, and Tagarro I
- Subjects
- Administration, Oral, Analgesics, Opioid administration & dosage, Breakthrough Pain etiology, Controlled Clinical Trials as Topic, Drug Tolerance, Fentanyl administration & dosage, Humans, Mouth Mucosa metabolism, Neoplasms complications, Analgesics, Opioid therapeutic use, Breakthrough Pain drug therapy, Fentanyl therapeutic use
- Abstract
Oral normal-release morphine has long been considered the gold-standard treatment for cancer breakthrough pain. However, its relatively long time to analgesic onset, delay in maximal analgesic effect and prolonged duration of action make it unsuitable for the management of breakthrough pain episodes. These limitations led to the development of an oral transmucosal formulation of the fast-acting opioid fentanyl (oral transmucosal fentanyl citrate [OTFC] lozenge on a plastic handle; Actiq®), which has been shown to produce more rapid and effective pain relief than oral morphine. However, the formulation itself has some limitations. Consequently, investigators have continued to develop other, newer generation, transmucosal formulations of fentanyl to further improve the management of breakthrough pain. Recently, five such compounds (Effentora®/Fentora®, Abstral®, Instanyl®, Breakyl®/OnsolisTM and PecFent®) have been concurrently approved in Europe and/or the US, and have documented efficacy in quickly relieving breakthrough pain episodes. All of the available pivotal efficacy trials of these agents are randomized, double-blind comparisons with placebo. There are no head-to-head trials comparing any of the newer transmucosal formulations with each other. Only one non-pivotal study of intranasal fentanyl spray used a transmucosal preparation as an active comparator. However, that comparator was OTFC, not one of the newer transmucosal products. Close examination of the existing trials assessing these newer transmucosal preparations reveals significant variation in many study parameters, such as patient selection criteria, severity of breakthrough pain episodes, proportions of patients with a neuropathic pain component, titration protocols, choice of the primary endpoints, protocols for repeat dosing and rescue medication, the separation of treated episodes and the extent of the placebo response, all of which may have affected efficacy results. It is therefore difficult to evaluate the relative efficacies of these treatments on the basis of the available trials. Furthermore, given the differences in design between studies, the value of any potential meta-analyses including these trials would likely be limited. Blinded head-to-head comparisons of new transmucosal fentanyl preparations would be the only way to conclusively determine comparative effectiveness, but given the impracticalities of conducting such studies, these are unlikely.
- Published
- 2011
- Full Text
- View/download PDF
36. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers.
- Author
-
Vasisht N, Gever LN, Tagarro I, and Finn AL
- Subjects
- Administration, Buccal, Adult, Analgesics, Opioid adverse effects, Analysis of Variance, Area Under Curve, Chromatography, High Pressure Liquid, Electrocardiography drug effects, Female, Fentanyl adverse effects, Half-Life, Humans, Male, Naloxone pharmacology, Narcotic Antagonists pharmacology, Nonlinear Dynamics, Oximetry, Reproducibility of Results, Tandem Mass Spectrometry, Young Adult, Analgesics, Opioid administration & dosage, Analgesics, Opioid pharmacokinetics, Fentanyl administration & dosage, Fentanyl pharmacokinetics
- Abstract
Fentanyl buccal soluble film (FBSF) is a rapidly absorbed transmucosal formulation of fentanyl for the management of breakthrough pain in opioid-tolerant patients with cancer. This open-label, 3-period, sequential dose study evaluated the dose-to-dose reproducibility of the pharmacokinetics of fentanyl following the administration of 600- or 1800-microg doses of FBSF in 12 naltrexone-blocked, healthy adult volunteers. Subjects received 3 study treatments: single doses of 600 microg of FBSF on day 1 and day 4 and three 600-microg doses administered at 1-hour intervals on day 7. Plasma fentanyl concentrations were measured over a 48-hour period after each single dose of FBSF and 72 hours after the 3-dose regimen. Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons). C(max) and overall fentanyl exposure (AUC(inf)) increased approximately 3-fold with the 3-dose regimen compared with the single-dose periods. Fentanyl plasma concentrations following single doses of FBSF were reproducible, and 3 doses administered 1 hour apart produced a tripling in exposure and maximal concentration compared with a single dose.
- Published
- 2010
- Full Text
- View/download PDF
37. Single-dose pharmacokinetics of fentanyl buccal soluble film.
- Author
-
Vasisht N, Gever LN, Tagarro I, and Finn AL
- Subjects
- Administration, Buccal, Adult, Analgesics, Opioid therapeutic use, Area Under Curve, Biological Availability, Cross-Over Studies, Dose-Response Relationship, Drug, Female, Fentanyl therapeutic use, Humans, Male, Mouth Mucosa metabolism, Time Factors, Treatment Outcome, Young Adult, Analgesics, Opioid administration & dosage, Analgesics, Opioid pharmacokinetics, Fentanyl administration & dosage, Fentanyl pharmacokinetics, Pain drug therapy
- Abstract
Objective: The objectives of the study were to determine the absolute bioavailability of fentanyl from fentanyl buccal soluble film, estimate the percentage of a fentanyl dose absorbed through the buccal mucosa, and compare the bioavailability of equivalent doses administered either as single or multiple dose units., Design: Open-label, randomized, four-period, Latin-square crossover pharmacokinetic study., Setting: Inpatient phase 1 unit., Patients: Twelve healthy volunteers. Interventions. Injectable fentanyl citrate (200 microg) administered by intravenous infusion, injectable fentanyl citrate (800 microg/16 mL) administered orally, and fentanyl buccal soluble film (800 microg) administered as a single film and as four separate 200 microg films simultaneously., Outcome Measures: Plasma concentrations after fentanyl dosing; pharmacokinetic parameters., Results: The two buccal film treatments were bioequivalent and both had an absolute bioavailability of 71%. The percentage of an administered dose absorbed through the buccal mucosa was calculated to be 51%., Conclusions: Fentanyl buccal soluble film effectively delivers a high percentage of the administered fentanyl dose and nearly identical plasma profiles are obtained when equivalent doses are delivered by single or multiple dosage units.
- Published
- 2010
- Full Text
- View/download PDF
38. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
- Author
-
Vasisht N, Gever LN, Tagarro I, and Finn AL
- Subjects
- Adhesives, Adult, Area Under Curve, Calibration, Cheek, Chemistry, Pharmaceutical, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Mouth Mucosa, Reference Standards, Young Adult, Analgesics, Opioid administration & dosage, Analgesics, Opioid pharmacokinetics, Fentanyl administration & dosage, Fentanyl pharmacokinetics
- Abstract
Background and Objectives: BioErodible MucoAdhesive (BEMA) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of breakthrough pain in opioid-tolerant patients with cancer. The generic name is fentanyl buccal soluble film (FBSF). The objectives of this study were to compare the pharmacokinetic profile of FBSF formulations at three different pHs (pH 6, pH 7.25 and pH 8.5) and to understand the differences in the pharmacokinetics of fentanyl from FBSF compared with that of oral transmucosal fentanyl citrate (OTFC)., Methods: This was a randomized, open-label, single-dose, four-period, Latin-square crossover study consisting of a 9-day inpatient treatment period. The study was conducted at a phase 1 clinical research unit in Austin, TX, USA. Twelve healthy subjects were enrolled, nine males and three females, between the ages of 21 and 44 years. Each subject received four 800 microg doses of fentanyl: single doses of the three FBSF formulations (pH 6, pH 7.25 and pH 8.5) and OTFC, with concurrent naltrexone. Plasma fentanyl concentrations were measured over a 48-hour period after each study dose. Pharmacokinetic parameters were calculated and compared., Results: Peak plasma fentanyl concentrations (Cmax) and overall fentanyl systemic exposure (area under the plasma concentration-time curve from time zero extrapolated to infinity [AUCinfinity]) for each of the three FBSF formulations were greater than for OTFC. The pH 7.25 FBSF formulation provided the earliest time to reach Cmax (tmax), the highest Cmax value and the greatest AUC(infinity) value. Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03 ng/mL; p<0.05). Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUCinfinity 14.5 vs 10.3 ng . h/mL)., Conclusions: All three FBSF formulations produced greater peak plasma concentrations and overall exposure to fentanyl than OTFC. In particular, the pH 7.25 FBSF formulation showed the most favourable pharmacokinetic profile of the three FBSF formulations. In comparison with OTFC, the pH 7.25 FBSF formulation produced the fastest and most efficient fentanyl delivery and was selected for further clinical development.
- Published
- 2009
- Full Text
- View/download PDF
39. Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet).
- Author
-
Cnota PJ, Nowak H, Tagarro I, Erb K, Schürer M, Schulz HU, and Maus J
- Abstract
Introduction: Different oral sustained-release (SR) formulations of tramadol have been introduced in pain treatment in order to prolong the dosage interval to improve convenience for the patient. The objective of this study was to compare tramadol pharmacokinetics and intra- and intersubject variability after replicate single-dose administrations of a multiple-units SR formulation (capsule) and a single-unit formulation (tablet)., Methods: This was a randomised, single-dose, single-centre study with an open-label, four-period, two-sequence, two-formulation, replicate crossover design in healthy subjects under fed conditions. The main outcome measures were the intra- and intersubject variance of the area under the concentration-time curve from 0 to 12 hours (AUC(12)) and maximum concentration (C(max)), as well as the mean AUC(12) and C(max) for tramadol. Study drugs were a tramadol SR multiple-units formulation (capsule) and a tramadol SR single-unit formulation (tablet), each containing tramadol hydrochloride 100mg. The time interval from 0 to 12 hours of AUC(12) of the single-dose design corresponds to the recommended twice-daily dosage interval for both study drugs during long-term treatment., Results: The two formulations were equivalent in the area under the curve (AUC(infinity): 2411 vs 2527 mug . h/L). However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours). In addition, intrasubject variability of AUC(12) was significantly smaller for capsules than for tablets (p = 0.041). Capsules also produced smaller intra- and intersubject variability in plasma concentrations during the first 2.5 and 3.0 hours after administration, respectively (p < 0.05)., Conclusion: Although tramadol SR capsules and tramadol SR tablets led to an equivalent systemic exposure to the drug, capsules provided a smoother and more extended plasma profile. In addition, in the case of capsules, bioavailability was subjected to lower variability in terms of both rate and extent of absorption.
- Published
- 2005
- Full Text
- View/download PDF
40. Pharmacokinetic assessment of a fast-release orodispersible tramadol tablet compared to a conventional tramadol capsule.
- Author
-
Tagarro I, Vauzelle-Kervroedan F, and Díez MC
- Subjects
- Adolescent, Adult, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Area Under Curve, Biotransformation, Capsules, Cross-Over Studies, Humans, Male, Tablets, Therapeutic Equivalency, Tramadol administration & dosage, Tramadol adverse effects, Analgesics, Opioid pharmacokinetics, Tramadol pharmacokinetics
- Abstract
The purpose of this clinical trial was to compare the pharmacokinetics of a recently developed fast-release orodispersible tramadol tablet (CAS 27203-92-5, Zamadol Melt) to that of a conventional tramadol capsule. This new formulation, once placed into the mouth, disintegrates rapidly in contact with the saliva. Therefore, when the saliva is swallowed, the drug reaches the gastrointestinal tract. In an open, randomised, two-period, crossover study performed in 20 healthy volunteers, the orodispersible tramadol tablet and a conventional tramadol capsule were administered. Even although the galenics of both products are far different, statistical analysis of pharmacokinetic parameters allows concluding bioequivalence, not only for the parent molecule (tramadol), but also for its active metabolite O-desmethyl tramadol. This orally dispersible formulation, being bioequivalent to the standard capsules so far used, has the practical advantage that it can be taken without liquids. This facilitates an early treatment of emergent pain, irrespective of the place or situation where it may arise.
- Published
- 2004
- Full Text
- View/download PDF
41. Chromosomal localization of human satellites 2 and 3 by a FISH method using oligonucleotides as probes.
- Author
-
Tagarro I, Fernández-Peralta AM, and González-Aguilera JJ
- Subjects
- Base Sequence, Humans, Molecular Sequence Data, Oligonucleotide Probes, Chromosome Mapping methods, Chromosomes, Human, DNA, Satellite genetics, In Situ Hybridization, Fluorescence methods
- Abstract
Classical satellites I, II and III are composed of a mixture of repeated sequences. However, each of them contains a simple family of repeated sequences as a major component. Satellites 2 and 3 are simple families of repeated sequences that form the bulk of human classical satellites II and III, respectively, and are composed of closely related sequences based on tandem repeats of the pentamer ATTCC. For this reason, extensive cross-hybridizations are probably responsible for the similar in situ hybridization patterns obtained for satellites II and III. We have used a fluorescent in situ hybridization method with highly specific oligonucleotides for satellites 2 and 3, respectively, as probes. Our results show that satellite 2 is mainly located on chromosomes 1, 2, 10 and 16, whereas the major domain of satellite 3 is on chromosome 9. Furthermore, minor sites of satellites 2 and 3 are shown. Two-colour in situ hybridizations have enabled us to define the spatial relationships existing between the major domains of both satellites and centromeric alpha satellite sequences. These experiments indicate that the heterochromatin regions of chromosomes 1, 9 and 16 have different molecular organizations.
- Published
- 1994
- Full Text
- View/download PDF
42. Assignment of human satellite 1 DNA as revealed by fluorescent in situ hybridization with oligonucleotides.
- Author
-
Tagarro I, Wiegant J, Raap AK, González-Aguilera JJ, and Fernández-Peralta AM
- Subjects
- Base Sequence, Centromere chemistry, Consensus Sequence, Humans, Molecular Sequence Data, Chromosomes, Human, Pair 13 chemistry, Chromosomes, Human, Pair 3 chemistry, Chromosomes, Human, Pair 4 chemistry, DNA, Satellite analysis, In Situ Hybridization, Fluorescence methods, Oligonucleotide Probes
- Abstract
We have used a fluorescent in situ hybridization procedure to detect human satellite 1 DNA, the simple sequence family that constitutes the non-male-specific fraction of classical satellite 1 DNA. Satellite 1 appears to be located on pericentromeric regions of chromosomes 3, 4 and 13, and on satellites of each acrocentric chromosome. These results suggest a possible relationship between quinacrine fluorescence of heterochromatin and DNA composition. Furthermore, by means of multicolour in situ hybridization, we have spatially resolved satellite 1 sequences and centromeric alpha-satellite within heterochromatic blocks.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.